Skuldtech becomes Acobiom

08-Jul-2014 - France

Skuldtech changed its name to Acobiom.  The new name is intended to confirm the company’s strategic shift towards personalized medicine, which started in 2009 and represents a major opportunity for the medicine of the future.
 
Personalized medicine tailors treatment to the patient’s biological characteristics. It is one of the most promising approaches in oncology and in the targeted treatment of neurodegenerative diseases and some infections.  
 
In taking the name Acobiom, the company seeks to promote and develop its companion diagnostics and its expertise in the discovery of new biomarkers. It also embodies their strong position within ‘omics’ technologies. In the coming months Acobiom plans to bring new companion diagnostics to market and to launch new clinical trials for cancer.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...